DBV Technologies S.A. — FY 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; filed March 7, 2024. This is an annual report, not a standalone Q4 report. DBV is a clinical-stage biopharmaceutical company developing Viaskin epicutaneous immunotherapy patches. It had no product sales or approved products during the year.
Financial performance and liquidity
| Metric | FY 2023 | FY 2022 |
|---|---|---|
| Revenue from product sales | $0 | $0 |
| Operating income, primarily tax credits and other operating income | $15.7 million | $4.8 million |
| Operating expenses | $92.2 million | $101.5 million |
| Loss from operations | $76.4 million | $96.6 million |
| Net loss | $72.7 million | $96.3 million |
| Basic and diluted loss per share | $0.76 | $1.24 |
| Net cash used in operating activities | $79.7 million | $55.7 million |
| Cash and cash equivalents at year-end | $141.4 million | $209.2 million |
- Research and development expense was $60.2 million, versus $75.5 million; reported 2023 expense benefited from reversals associated with ending the Nestlé collaboration, despite increased clinical activity and external trial costs.
- General and administrative expense rose 21% to $29.5 million, including higher financing-related professional fees. Sales and marketing expense rose 52% to $2.4 million, mainly due to Viaskin Peanut pre-commercialization work.
- Operating income included $8.8 million of French research tax credits and $7.0 million of other operating income. The company reports no bank debt or financial debt at year-end. Total liabilities were $42.8 million; these include lease and operating liabilities.
- Cash declined by $67.8 million during 2023. Financing provided $6.8 million, mainly from the ATM offering; the comparable 2022 financing included a $194 million PIPE.
Business developments and changes
- Viaskin Peanut for toddlers: Phase 3 EPITOPE results met the prespecified primary endpoint. At 12 months, 67.0% of treated toddlers were responders versus 33.5% on placebo. FDA feedback did not require another efficacy study, but did require additional safety data; DBV submitted a revised design for the COMFORT Toddlers safety study in Q4 2023.
- Longer-term toddler data: Interim EPOPEX results reported in November 2023 showed 83.9% of evaluated participants met responder criteria after 24 months. These were open-label extension findings, not a new placebo-controlled pivotal result.
- Viaskin Peanut for ages 4–7: The VITESSE Phase 3 trial of a modified, larger circular patch began screening participants in 2023. The company anticipated last-patient screening by Q3 2024 and topline results in the first half of 2025. A supplemental controlled safety study, COMFORT Children, was planned for 2024.
- The prior U.S. BLA for children ages 4–11 was not approved: FDA issued a Complete Response Letter in 2020, citing patch adhesion/effectiveness, modified-patch supporting data, human-factors work, and additional manufacturing information. DBV is pursuing a new pivotal path with the modified patch in younger children.
- The EU application was withdrawn in 2021 after the EMA raised a major objection concerning the limitations of evidence from a single pivotal study. DBV said it intends to resubmit when additional pivotal data are available.
- DBV terminated its Nestlé Health Science collaboration for the MAG1C diagnostic program in October 2023. The termination generated material accounting reversals and left DBV responsible for its own wind-down costs and remaining study costs.
Outlook, risks and unusual items
- Going concern: Management estimated year-end cash would fund operations through December 31, 2024, but also stated that, as of the filing date, available cash was not projected to support the operating plan for at least the next 12 months. The auditors identified substantial doubt about the company’s ability to continue as a going concern. DBV expects to seek debt or equity financing before year-end 2024; there is no assurance funding will be available on acceptable terms.
- DBV expects ongoing research, regulatory, clinical-trial and potential launch preparation costs. The filing gives trial milestones but does not provide revenue guidance or a projected profitability date.
- Clinical and regulatory execution remains uncertain: FDA requested additional safety data, and VITESSE must demonstrate efficacy and patch adhesion. The company also depends on third-party clinical organizations and a limited supplier/manufacturer base.
- Cash commitments include approximately $44.2 million of operating leases and CRO purchase obligations in the MD&A table, including $22.7 million scheduled for 2024. The financial-statement notes separately cite CRO commitments of $64.4 million through 2025; the filing text does not provide a clear reconciliation of these figures.
- DBV received a Nasdaq notice in December 2023 for ADS bids below $1.00 and had until June 17, 2024 to regain compliance, subject to Nasdaq rules. Potential dilution is also material: 28.3 million pre-funded warrants remain outstanding, in addition to options, RSUs and other awards.
- Other material risks include competing food-allergy treatments, uncertain reimbursement and commercialization capability, manufacturing scale-up, clinical safety (including reactions during food challenges), intellectual-property protection, and foreign-exchange exposure.
Most important facts for investors to verify
- Current cash, actual monthly cash burn, financing completed since the filing, and whether the going-concern assessment has changed.
- FDA interactions and timing for COMFORT Toddlers, COMFORT Children, and the Viaskin Peanut BLA strategy; VITESSE enrollment and readouts.
- The complete accounting and cash impact of the Nestlé termination, including the reported reversals and remaining study obligations.
- The basis for the differing CRO commitment totals ($44.2 million versus $64.4 million) and the current timing of those payments.
- Nasdaq bid-price compliance status and potential dilution from warrants, equity awards, or further capital raises.